CA2315397C — Arylthiazolidinedione derivatives
Assigned to Merck and Co Inc · Expires 2007-08-07 · 19y expired
What this patent protects
Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and a re therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia a nd hypertriglyceridemia), atherosclerosis, obesity, vascular reste…
USPTO Abstract
Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and a re therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia a nd hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR .alpha., .delta. and/or .gamma. mediated diseases , disorders and conditions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.